Specialty Pharmacy

 

DUBLIN — Allergan’s has completed its $1.7 billion acquisition of clinical-stage biopharma company Tobira Therapeutics, the company announced Tuesday. Tobira focuses on developing and commercializing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. Allergan paid $28.35 per share of the company, as well as contingent value rights, potentially payable upon completion of certain development, regulatory and commercial milestones. 

 

NEW YORK — Pfizer has discontinued the global clinical development program around its investigational high cholesterol treatment bococizumab, the company announced Tuesday, noting that because of information available about the treatment and the current market landscape, it wasn’t likely to create value for patients, doctors or shareholders. 

 

TOKYO and MAINZ, Germany — In a move that would expand its oncology pipeline, Astellas Pharma announced Friday its agreement to acquire Ganymed Pharmaceuticals for €422 million, or about $461 million. 

 

Under the agreement, Astellas would acquire 100% of the equity in Ganymed and Ganymed shareholders will be able to receive up to €860 million in further contingent payments tied to the progress of Ganymed’s most advanced clinical program, IMAB362. Ganymed would become a wholly owned subsidiary of Astellas. 

PHILADELPHIA — The statewide trade organization for life sciences company in Pennsylvania, which has been named Pennsylvania Bio, announced Wednesday that it would be changing its name and brand. 

 

LAS VEGAS — In a move aimed at addressing the two challenges of discovering new options for treatment and improving chronic disease management, Teva and IBM on Wednesday announced an expansion of their e-health alliance, with both projects running on the IBM Watson Health Cloud. 

 

FLINT, Mich. — Diplomat Pharmacy has announced big changes to its leadership team, including a new president and the departure of its CFO. 

 

As Diplomat president Gary Kadlec prepares to retire, effective Dec. 31, and serve out his term on the company’s board, Diplomat has named Paul Urick president, effective Nov. 1. Urick moves up from his position as Diplomat’s SVP industry relations, pharmaceutical account management and payer strategy.